原发性膜性肾病采用吗替麦考酚酯的效果分析

Effect of Mycophenolate Mofetil on Primary Membranous Nephropathy

目的分析原发性膜性肾病采用吗替麦考酚酯的效果。方法将我院2015 年5 月—2018 年2 月确诊并收治的116 例原发性膜性肾病的患者按照随机数字表法分为研究组和对照组,每组58 例。对照组应用泼尼松及环磷酰胺进行治疗,研究组应用泼尼松及吗替麦考酚酯进行治疗。对比两组疗效,对比两组治疗前后24 h 尿蛋白、血清总蛋白、血清肌酐水平,观察两组不良反应。结果研究组总有效为70.69%,高于对照组的51.72%(P < 0.05),其治疗后24 h 尿蛋白、血清总蛋白、血清肌酐无差异,改善幅度好于对照组(P < 0.05)。两组均无不良反应发生。结论原发性膜性肾病采用吗替麦考酚酯疗效确切,可恢复肾功能并改善肾病综合征症状,安全性好。

Objective To analyze the effect of mycophenolate mofetil on primary membranous nephropathy. Methods 116 cases of primary membranous nephropathy diagnosed and treated in our hospital from May 2015 to February 2018 were divided into study group and control group according to random number table method, 58 cases in each group. The control group was treated with prednisone and cyclophosphamide, while the study group was treated with prednisone and mycophenolate mofetil. The curative effect of the two groups was compared. The 24 h urinary protein, serum total protein and serum creatinine were compared before and after treatment, and the adverse reactions of the two groups were observed. Results The total effective rate was 70.69% in the study group, which was significantly higher than 51.72% in the control group (P < 0.05). There was no significant difference in urinary protein, serum total protein and serum creatinine 24 hours after treatment between the study group and the control group (P < 0.05).There were no obvious adverse reactions in both groups. Conclusion Mycophenolate mofetil is effective in treating primary membranous nephropathy, which can significantly restore renal function and improve the symptoms of nephrotic syndrome with good safety.